ART I02

Drug Profile

ART I02

Alternative Names: AAV5.NF-kB.IFN-β; Recombinant AAV type2/5 containing a hIFN-b gene

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arthrogen
  • Class Antirheumatics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rheumatic disorders

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Rheumatic disorders in Netherlands (Intra-articular) (NCT02727764)
  • 16 Feb 2017 Arthrogen receives clinical trial approval for a phase Ib trial in Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top